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ABSTRACT
The objective of the current study was to investigate the feasibility of Theophylline and
Nicotinamide pharmaceutical co-crystals by hot melt extrusion technology and to evaluate the
processability by using HPMCAS-MG and PEO as polymer carriers. Theophylline, a BCS class I
was chosen as a model drug and Nicotinamide, a vitamin B family was selected as a suitable coformer for the co-crystals study. HPMCAS-MG, a synthetic polymer and PEO, water-soluble
polymer were chosen as polymer carriers for the study. To optimize the process parameters and
formulations, a physical mixture of 1:1 molar ratio of theophylline and nicotinamide were
prepared. Physical mixture was extruded through the co-rotating twin-screw extruder (11mm
Process 11, Thermo Fisher Scientific) utilizing a modified screw configuration. The extrusion was
performed at different temperatures and screw speeds. The temperatures used for the experiment
were 140C, 150C, 160C and 170C along with a screw speed of 50 rpm. The presence of mixing
and temperature were found to be the critical parameters that influence the formation of co-crystals
during extrusion processing. The solid state of the samples was analyzed by Differential scanning
calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and X-ray powder
diffractometry (PXRD). A Scanning electron microscopy (SEM) was conducted to study the
morphology of the extrudates. The in vitro drug release study was performed and the results
indicate that the co-crystals exhibited a relatively high drug release in 5mins when compared to
the pure theophylline and the co-crystals with PEO as carrier showed better dissolution profile
when compared to the one with HPMCAS-MG as carrier. The co-crystals were stable for three
months at accelerated stability conditions of 40 (±2) C and 75 (±5) % RH.
ii
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1. INTRODUCTION

Hot melt extrusion (HME) processing was established in the early 1930s and was widely applied
processing technology in the plastic, rubber and food industries. The application of HME expanded
to the pharmaceutical industry at the beginning of the 1970s and was used in the formulation and
product development as well as in the manufacturing sector[1]. Melt extrusion is currently applied
in the pharmaceutical field for the manufacture of variety of dosage forms such as granules, pellets,
tablets, implants, suppositories, stents, transdermal systems, and ophthalmic inserts [2]. HME is a
continuous pharmaceutical process that involves pumping polymeric materials with a rotating
screw at temperatures above their glass transition temperature (Tg) and sometimes above the
melting temperature (Tm) to achieve molecular level mixing of the active compounds along with
thermoplastic binders, polymers or both [1]. Hot melt extrusion has a potential of continuous
manufacturing, better inline monitoring, automation and reduction in capital and labor costs [3].
However, there are some disadvantages to the products manufactured via HME. These are related
to the high energy input from the applied shear forces and high temperature that could lead to drug
or polymer degradation and significantly impacts the product quality [4]. Regulatory bodies
support the investment in the use of quality by design (QbD) and process analytical technology
(PAT), the two essential tools in the HME process, to enhance product and process understanding.
PAT tools including Raman and near-infrared spectroscopy plays an important role in real time
quality evaluation and understanding of the extrusion process in the production of pharmaceutical
dosage forms [1]. In drug discovery and development, industry estimates that more than 50% of
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active pharmaceutical ingredients currently used belong to the biopharmaceutics classification
system II (BCS class II), characterized as poorly water soluble compounds and results in
formulations with low bioavailability. Hence, there is a critical need for the pharmaceutical
industry to develop formulations that will enhance the solubility and bioavailability of the
compounds. HME technology provides an opportunity to earn intellectual property, which is
evident from an increasing number of patents and publications that have included it as a novel
formulation technology [1].
An important criterion of solid-state pharmaceutical development is to increase drug solubility
while maintaining a stable form [5]. Co-crystals have emerged as an emerging approach to modify
solubility, dissolution, and other physiochemical properties of the drug substances [5]. Co-crystals
provide a different pathway, where any API regardless of acidic, basic, or ionizable groups could
be potentially co crystallized [6]. Pharmaceutical co-crystals provide an alternative to chemical
modification of the drug substance as well as salt forms, amorphous, solvate and polymorphic drug
forms that all have limitations in their utility [5]. By co-crystallization, a crystalline complex of
two or more molecules is constituted, including API, bonding together in the crystal lattice through
non-covalent interactions such as hydrogen bonding [7]. A pharmaceutically acceptable, nontoxic
co-former must be chosen to result in a pharmaceutically acceptable co-crystal [6]. Nevertheless,
the formation of co-crystals of an API with excipient, a different drug molecule, or a solubilizing
agent, provides the opportunity to design delivery systems at the molecular level and to enhance
their pharmaceutical properties [8]. Robustness of potential intermolecular interaction and
hydrogen bonding rules are the important aspects of co-crystallization experiment design [6].
Screening and selecting a polymorphic form for a drug product is creating a balance between good
solubility (amorphous) and stability (crystalline). If co-crystals are compared to salts, the
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difference is that no proton transfer occurs in co-crystal formation [9]. Traditionally co-crystals
have been prepared by slow evaporation or by neat grinding techniques. In recent years, liquid
assisted grinding has been developed as a more effective method for preparing co-crystals. In
addition co-crystals have also been prepared by melt crystallization, sublimation and solution
crystallization. Of all the techniques mentioned above, it has been found that solution
crystallization has proven to be a practical scalable process, due to the ease in reproducibility,
phase control and particle size control [10]. However, co-crystal scale up is the major challenge
and disadvantage of solution crystallization as knowledge of the ternary phase diagram between
the co-crystal constituents and the solvent is necessary and measurement of such phase diagrams
involves a large number of experiments which is extremely difficult and time consuming. Twin
Screw Extrusion (TSE) of co-crystal components acts as a scalable and solvent-less process that
provides a viable alternative to solution crystallization. It acts as an excellent method of producing
co-crystals as well an easily amenable technique to a quality-by-design (QbD) approach [10].
Although co-crystals have been known recently, they are a poorly studied class from the viewpoint
of pharmaceuticals [9].
The purpose of this work is the development of Theophylline Nicotinamide co-crystals utilizing
Hot Melt Extrusion (HME) technology. Theophylline, which is used for the treatment of
respiratory diseases such as asthma, is selected as the API. It exists as four anhydrate polymorphs
and as a monohydrate form. Nicotinamide, a member of the vitamin B family is chosen as the coformer for the formation of co-crystals. It exists as four polymorphs. Dosage forms produced by
hot melt extrusion method requires a pharmaceutical grade thermoplastic polymer [11]. The two
polymer carriers employed for the study were HPMCAS and PEO. Aquasolve HPMCAS-MG, a
water insoluble polymer is widely used as a solid dispersion carrier for bioavailability
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enhancement of poorly soluble compounds. It is also used as an enteric film-coating polymer for
tablets and capsules [12](11). PEO, a free flowing thermoplastic homo polymer is miscible with
water in all ratios due to the hydration of ether oxygen [11]. HPMCAS polymers have a Tg of
120°C and PEO, a semi crystalline polymer with a melting range of 57-73°C. In this current study,
the effect of HPMCAS-MG and PEO as polymeric carriers was examined to assess the
processability of the developed Theophylline Nicotinamide pharmaceutical co-crystals.
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2. MATERIALS AND METHODS
2.1. Materials
Pure Theophylline Anhydrous and Nicotinamide were purchased from Sigma-Aldrich, Inc.
(Milwaukee, WI) and used as received. Aquasolve™ Hydroxypropyl Methylcellulose Acetate
Succinate HPMC-AS MG grade was obtained from Ashland Inc. (Wilmington, DE) and PEO was
obtained from Colorcon Inc. All solvents used for HPLC analysis were of analytical grade.

2.2. Methods
2.2.1. Thermogravimetric Analysis (TGA)
TGA was performed only for Nicotinamide (co-former) to establish the processing temperatures
for extrusion, stability and thermal degradation using a Perkin Elmer Pyris 1 TGA running Pyris
manager software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., Connecticut,
USA). Five to seven milligrams of the sample were weighed in an aluminum pan and heated from
25°C to 450°C at 10°C/min heating rate under nitrogen atmosphere.
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2.2.2. Hot Melt Extrusion (HME) processing
Theophylline and Nicotinamide in 1:1 molar ratio were weighed and blended thoroughly in a V
blender (GlobePharma) for 10 minutes. Co-crystallization was carried out using a 11mm corotating twin-screw extruder (Thermo Fisher Scientific) having a length to diameter ratio of
(L|D:40) with a customized screw design employing several mixing elements. The prepared blend
was charged to the extruder into the extruder hopper at 5% feed rate. The extruder was operated
with and without a die. 5% of HPMCAS-MG and 5% of PEO were employed as polymeric carriers
for the study. Preliminary studies revealed that the optimal processing temperature should not
exceed 170°C for the extrusion process. The screw speed was fixed at 50rpm.

Figure 1. Schematic representation of the Modified Screw Configuration
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2.2.3. Solid State Characterization
2.2.3.1. Differential Scanning Calorimetry (DSC)
Thermal behavior of the physical blend and the extruded formulations were examined by
differential scanning calorimetry (DSC) (TA instruments DSC 25 Discovery series, New Castle,
DE) coupled with a refrigerated cooling system. The accurately weighed samples (5-10mg) were
placed in a hermetically sealed aluminum pans and heated from 25°C to 300°C at a heating rate of
10°C. min-1. Nitrogen at the flow rate of 20 ml|min was used as purge gas. Calibration of the
instrument was preformed using indium as standard. After each scan was completed the melting
points were analyzed and Trios manager software was used for the data analysis.
2.2.3.2. Fourier Transform Infrared Spectroscopy (FTIR)
Intermolecular hydrogen bonding between drug and co-former was determined by using Fourier
transform infrared spectrometer (Agilent Technologies Cary 660, Santa Clara, CA). The scan
range was 400-4000 cm-1, using 100 scans per spectrum with a resolution of 4cm-1. The bench was
equipped with an ATR (Pike Technologies MIRacle ATR, Madison, WI), which was fitted with a
single-bounce, diamond coated ZnSe internal reflection element.
2.2.3.3. Powder X-Ray Diffraction (PXRD)
The crystallinity of pure theophylline, pure nicotinamide and the extrudates was assessed by Xray powder diffraction using a Bruker D8 Focus X-ray diffractometer operated at a voltage of 40
kV and a current of 40 mA. Powder was packed into the sample holder. Data for each sample were
collected in the 2Θ angle range of 4–40° over 10 min in continuous detector scan mode. The
process parameters were set as scan-step size of 0.02° (2Θ) and scan-step time of 0.3 s.
2.2.3.4. Scanning Electron Microscopy (SEM)
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The morphological characteristics of the pure theophylline, pure nicotinamide and the extrudates
were examined using SEM (JEOL JSM-5600) that was operated at an accelerating voltage of 5 kV
under analysis mode. Each specimen was fixed by conductive double-sided carbon adhesive tape
and gold-sputter coated by a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in
a high-vacuum evaporator prior to the test to avoid electrostatic charging. Four magnifications (25,
50, 100, and 250) were employed to give more accurate and clear understanding of results.
2.2.4. Pharmaceutical Characterization
2.2.4.1. Compressibility Index and Hausner’s Ratio
The flow characteristics of the pure theophylline and the theophylline-nicotinamide extrudates (cocrystals) were predicted by Carr’s compressibility index and Hausner’s Ratio. For the
compressibility index and hausner’s ratio, the generally accepted scale of flowability is given in
table 1.
Table 1. Accepted scale of flowability for Compressibility index and Hausner’s ratio
Compressibility Index (%)

Flow Character

Hausner’s Ratio

< 10

Excellent

1.00-1.11

11-15

Good

1.12-1.18

16-20

Fair

1.19-1.25

21-25

Passable

1.26-1.34

26-31

Poor

1.35-1.45

32-37

Very poor

1.46-1.59

> 38

Very, very poor

> 1.60
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2.2.4.2. Loss on Drying
The moisture balance (Ohaus) was employed to investigate the moisture content of pure
theophylline and theophylline-nicotinamide co-crystals by measuring the uptake and loss of vapor.
2.2.4.3. In vitro dissolution study
Dissolution studies were carried out in a USP II paddle apparatus (Hanson Virtual Instruments).
Equal amounts of 100 mg of pure theophylline, theophylline nicotinamide extrudates were added
to 900 ml of water in each dissolution vessel (n=3). The temperature of the medium was maintained
at 37°C with a paddle rotation of 50 rpm. About 1-2ml of samples was withdrawn at 5, 15, 30, 45,
60, 90 and 120 min intervals and filtered with a 200μm filter prior to HPLC analysis.
2.2.4.4. Drug content analysis
Quantitative high performance liquid chromatography (HPLC) was carried out as reported in USP
38 on an isocratic high performance liquid chromatography (Waters Corp., Milford, MA, USA)
equipped with
an auto sampler, UV/VIS detector and Empower software. The analytical column Phenomenex
Luna C18 (5 μm, 250 mm × 4.6 mm) was used to analyze theophylline at a detection wavelength
of 280 nm. The
composition of the mobile phase employed was 92:7:1 (% v/v/v) of 0.01 M sodium acetate
trihydrate buffer: acetonitrile: glacial acetic acid. The mobile phase was pumped from the solvent
reservoir to the column at a flow rate of 1ml/min. The samples were filtered through 0.22μ filter
(Millex® GV, Durapore® PVDF) before being injected into the column, and the injection volume
was 10 μl. The calibration curve was plotted by varying the standard solution concentration from
10-70 μg|ml.
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2.2.5. Physical and Chemical Stability
The stability study for all the extrudates was conducted and evaluated by Caron 6030 stability
chamber. The samples were evaluated for three aspects; physical appearance, drug content and
DSC. Samples were stored in the 15 ml HDPE vials at 25 (±2) °C/60 (±5) % RH and 40 (±2) °C/75
(±5) % RH and sealed with screw caps. Drug content and DSC analysis was obtained at zero day,
one-month, two months and three months.
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3. RESULTS AND DISCUSSION
3.1. Hot Melt Extrusion (HME) processing
The physicochemical properties of the API, and the polymeric carrier have to be considered
carefully, since they have a significant effect on the hot-melt extrusion processes as well as the
final output. Therefore, the process parameters of hot-melt extrusion should be accustomed based
on the physicochemical properties of each formulation component. Hot melt extrusion was
performed to determine the feasibility of producing pharmaceutical co-crystals. The screw was
designed for high mixing capacity and long residence time to enhance the conversion to co-crystal.
The screw design was setup with alternating 11mm segments of Zone A and Zone B throughout
the barrel. Co-crystals were collected in the powder form as the die, which is usually placed at the
end of the extruder, was removed, The screw configuration was adjusted to achieve high shear
intense mixing by assembling the kneading elements in three separate mixing zones. Temperature
profiles were found to play an important role in extrusion and influence the co-crystal properties.
Extrusion was performed at lower temperatures starting from 110°C to 150°C.It showed that the
formation of co-crystals could not take place at lower temperatures. Extrusion trials carried out at
different temperatures revealed that the temperature profile set at a maximum of 170°C showed
complete conversion of co-crystals with better quality when compared to those at 160°C. The
experiment clearly showed that the customized screw design provides an efficient mixing in the
extruder barrel and creates a new surface contacts continuously promoting co-crystal formation
[10]. In addition to increasing the temperature further optimization of the extrusion parameters like
screw speed was achieved for complete conversion of the co-crystal formation. The screw speed
10

was varied from 25 to 100 rpm. It is assumed that lower the screw speed the larger is the residence
time in the extruder [10]. Hence, a screw speed of 50 rpm was optimized as the final screw speed
with the torque in the range. With a lower screw speed, higher temperature, a residence time of 25 min was observed. Further, hot melt extrusion (HME) was performed by co-processing the drug,
co-former in the presence of polymeric carriers. 5% of HPMCAS and 5% of PEO were used as a
polymeric carrier along with equimolar quantities of drug and co-former in a 1:1 molar ratio. A
2mm rod shaped die was attached to the end of the barrel. The extrusion was performed at the
optimized conditions and was processed at a barrel temperature of 160°C and 170°C with a screw
speed of 50 rpm. The co-crystal formed this way become embedded in the matrix material, which
solidifies upon exiting the extruder. The co-crystals were collected in the form of rod shaped
extrudates. During the extrusion processing, it was observed that lower the matrix content, higher
the induced shear stress with a highest acceptable torque in the extruder in a range of 3 to 15 [14].
Table 2. Conditions and outcomes for optimized formulations during HME processes
Temperature (°C)

Screw Speed (Rpm)

Feed Rate (%)

Observed
Torque (%)

140 (F1)

50

5

6-15

150 (F2)

50

5

4-13

160 (F3)

50

5

3-8

170 (F4)

50

5

5-10

5% HPMCAS (F5)

50

5

8-12

5% PEO (F6)

50

5

9-13
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160°C 5%PEO

170°C 5%PEO

160°C 5%HPMCAS

170°C 5%HPMCAS

Figure 2. Images of the extrudates with 5% PEO and 5% HPMCAS

3.2. Solid State Characterization
3.2.1. Differential Scanning Calorimetry (DSC)
DSC studies were conducted on all formulations including pure Theophylline, pure Nicotinamide,
physical mixture, extrudates and also the formulations with 5% HPMC-AS MG and 5% PEO to
ascertain the impact of polymeric carriers during the processing of formulations and if it had any
effect on their thermal properties.
Nicotinamide has a melting peak at 129C and Theophylline at 273C. In the thermogram of the
theophylline nicotinamide physical mixture, two endothermic peaks appear, the first at the same
temperature as the melting peak of nicotinamide (128.2C) and another at 172C. Differential
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thermogram of all the extrudates indicated the presence of endothermal peak at about 126.4C,
which decreased and finally disappeared when higher extrusion temperature was used followed by
an exothermic peak leading to complete co-crystal conversion. A melting endotherm at 171.6C
which differs from the melting points of either theophylline (271.4C) or nicotinamide (128.2C)
occurred all the time indicating a new phase was formed between theophylline and nicotinamide
during hot melt extrusion. This is in accordance with the previous report of theophyllinenicotinamide co-crystal by co-grinding. [8]

Figure 3. DSC thermograms of pure theophylline, pure nicotinamide, physical mixture (PM) and
the extrudates at different temperatures
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Figure 4. DSC thermograms of F3 extrudates with polymeric carriers
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Figure 5. DSC thermograms of F4 extrudates with polymeric carriers
3.2.2. Fourier Transform Infrared Spectroscopy (FTIR)
Possible interactions between the components in co-crystals were investigated by FTIR. FTIR
spectra show more information about NH and NH2 groups. Theophylline contains two carbonyl
groups, which can be observed at 1662 cm-1 and 1706 cm-1. Nicotinamide has characteristic peaks
at 1616 cm-1 and 1675 cm-1. During co-crystallization of theophylline and nicotinamide, due to the
hydrogen bond formation these peaks were shifted to 1611 cm-1 and 1707 cm-1. Because to the NH stretching vibration, the FTIR spectra of theophylline contains 2969 cm-1 and nicotinamide
contains 3361cm-1. By formation of co-crystal, this characteristic peak was shifted to 3398 cm-1
due to the formation of hydrogen bonding.
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Figure 6. FTIR spectra of pure theophylline, pure nicotinamide, physical mixture (PM) and
extrudates at different temperatures

3.2.3. Powder X-Ray Diffraction (P-XRD)
X-ray diffractograms of physical mixture, pure components and processed co-crystals are
illustrated in Fig.6. The diffraction patterns were compared with the diffraction patterns of the pure
phases. In the XRPD diffractogram, Nicotinamide has a characteristic peak at 14.9° and
Theophylline at 12.7° [9]. The theophylline nicotinamide co-crystal has been observed to show a
characteristic peak at 13.4° indicating a new phase was formed during the extrusion processing of
theophylline and nicotinamide, which can be interpreted from fig 6.At both the extrusion
temperatures, the intensity of the co-crystal peak increased with decreasing screw speed. The
PXRD data supports the findings from the DSC and FTIR studies. Thus, co-crystal formation is
dependent on the non-covalent intermolecular hydrogen bonding interactions.
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Figure 7. PXRD diffractograms of pure theophylline, pure nicotinamide and the extrudates
3.2.4. Scanning Electron Microscopy (SEM)
SEM analysis showed the differences in the shape and size between extruded co-crystals and pure
components. As shown in Figure 7, pure theophylline has thin needle shaped crystals while
Nicotinamide has rod shaped crystals. The HME treated co-crystals were found to be clumped
with an undistributed geometry, with an irregular and deformed shape, as they did not undergo
further particle size reduction.
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Figure 8. Scanning electron microscopy (SEM) images of (a) pure theophylline, (b) pure
nicotinamide, (c) F4 extrudates, (d) extrudates with 5%HPMCAS, (e) extrudates with 5% PEO
3.3. Dissolution studies
In vitro dissolution studies were performed to assess the performance of the co-crystals compared
to the pure theophylline. The dissolution rate profiles for theophylline and theophylline
nicotinamide co-crystal in water are shown in Fig.8. A 60% dissolution was observed for the pure
theophylline at 5min and 70% dissolution was observed for theophylline nicotinamide co-crystal
which was comparatively higher amount than that of the pure theophylline. Drug release for
theophylline nicotinamide co-crystal reached a maximum of 95% at 15min. On the other hand,
pure theophylline showed 85% drug release at 15min. In addition, as shown in Fig.8, a plateau was
achieved at 45min for both the pure theophylline and theophylline nicotinamide co-crystal. The
dissolution profile of the co-crystals with polymer carriers such as PEO and HPMCAS-MG are
also shown in Fig.8. The dissolution enhancement was the most significant for the co-crystals
suspended in PEO, a semi crystalline polymer and had a comparative higher drug release to that
of co-crystals suspended in HPMCAS-MG, an amorphous polymer. The highest dissolution rate
of PEO is due to increased wetting of the co-crystals in the composites (14).The relatively low
dissolution of HPMCAS processed co-crystals may be due to the impact of enteric nature of
HPMCAS MG polymer.
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Figure 9. In vitro release profile of pure theophylline and extrudates

3.4. TGA and Drug Content
TGA data demonstrated that all formulations utilized in this study were stable under the employed
processing temperature (data not shown). The drug content analysis was performed in triplicates
with the extrudates equivalent to 50mg of pure theophylline. The analysis of drug content
confirmed the theoretical value of the formulations, with values ranging from 95% to 102%.
3.5. Pharmaceutical Characterization
3.5.1. Compressibility Index and Hausner’s Ratio
The flow properties of pure theophylline, the theophylline nicotinamide co-crystal with and
without the incorporation of polymeric carriers were assessed by checking the bulk and tap density.
The compressibility index and hausner’s ratio data are show in table 3. It is observed that the
theophylline nicotinamide co-crystal had better flow property than pure theophylline. The
compressibility index and hausner’s ratio for theophylline nicotinamide co-crystal was found to
be 25.99 and 1.35 when compared to the pure theophylline of 29.25 and 1.41. The extrudates with
polymeric carriers also had good flow property as compared to pure theophylline. The extrudates
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with HPMCAS-MG as polymeric carrier had an excellent flow property with a compressibility
index of 4.942 and hausner’s ratio of 1.052. On the other hand the extrudates with PEO as
polymeric carrier had a comparatively lesser flow property with a compressibility index of 23.7
and hausner’s ratio of 1.310 when compared to HPMCAS-MG but better than the pure
theophylline. This suggests the relatively improved characteristics of prepared pharmaceutical cocrystals.
Compressibility Index and Hausner’s Ratio can be calculated using measured values for bulk
density (ρbulk) and tapped density (ρtapped) as follows:
Compressibility Index = 100 ×

Hausner’s Ratio

=

ρtapped-ρbulk
ρtapped

ρtapped
ρbulk

Table 3. Compressibility Index and Hausner’s Ratio of pure theophylline and the extrudates
Samples

Compressibility Index

Hausner’s Ratio

Pure Theophylline

29.25 (poor)

1.413 (poor)

170°C50Rpm (F4)

25.99 (passable)

1.35 (passable)

5%HPMCAS (F5)

4.942 (excellent)

1.052 (excellent)

5%PEO (F6)

23.7 (passable)

1.310 (passable)
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3.5.2. Loss on Drying
The moisture content results for pure theophylline and their co-crystals are shown in table 4. The
observed results indicate that the theophylline nicotinamide co-crystals had consistently higher
percentage of moisture content than the pure theophylline. As shown in the table the observed
moisture content for pure theophylline was found to be 0.45% and the moisture content for
theophylline nicotinamide co-crystals were comparatively higher in the range of 0.6-0.7%. These
results indicate that the hygroscopicity of theophylline is remarkably increased when the co-crystal
of theophylline nicotinamide is formed. This suggests that co-crystals need to be stored in
appropriate packing.
Table 4. Moisture content of pure theophylline and the extrudates
Samples

Moisture Content (%)

Pure Theophylline

0.45

140C50Rpm (F1)

0.77

150C50Rpm (F2)

0.75

160C50Rpm (F3)

0.68

170C50Rpm (F4)

0.79

3.6. Stability
The results shown below shows that the extrudates were observed to be stable and showed no
degradation for three months at 25 (±2) °C/60 (±5) % RH and 40 (±2) °C/75 (±5) % RH.
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Figure 10. DSC thermograms of F3 extrudates at zeroth day, first month, second month and third
month at 25 (±2) °C and 60 (±5) % RH
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Figure 11. DSC thermograms of F3 extrudates at zeroth day, first month, second month and third
month at 40 (±2) °C and 75 (±5) % RH
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Figure 12. DSC thermograms of F4 extrudates at zeroth day, first month, second month and third
month at 25 (±2) °C and 60 (±5) % RH
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Figure 13. DSC thermograms of F4 extrudates at zeroth day, first month, second month and third
month at 40 (±2) °C and 75 (±5) % RH
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CONCLUSION
The application of Hot Melt Extrusion (HME) in the production of co-crystals has been
demonstrated for the model co-crystal system. Extrusion was found to be an effective and viable
method to develop co-crystals despite the mechanism of formation involved eutectic formation.
The parameters of the extrusion process that influenced the formation of co-crystals were
examined. It was observed that the temperature and extent of mixing in the extruder were the
primary process parameters that influenced the extent of conversion to the co-crystal during
extrusion processing [10]. The extrusion parameters like temperature, screw speed had an impact
on the quality of the developed co-crystals. Hot Melt Extrusion (HME) provides efficient and
intense mixing and close material packing of components which leads to the improved surface
contact between components thereby facilitating co-crystal formation without the use or need for
solvents. The experimental observations showed that the dissolution of co-crystals were relatively
higher when compared to the pure drug. The incorporation of polymer carriers like HPMCAS-MG
and PEO in the extrusion process provides further flexibility in optimizing co-crystal production.
Therefore, extrusion can be considered as an efficient, scalable and solvent free process for the
manufacture of co-crystals formation, which provides a viable alternative to solution
crystallization processes and other conventional techniques.
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